Megna Michael R sold $3.4M of KNSA
Megna Michael R (CHIEF ACCOUNTING OFFICER) sold 36,260 shares of Kiniksa Pharmaceuticals International, plc (KNSA) at an average of $94.43 ($91.87–$97.74, $3.42M total) across 7 trades on 2026-10-30 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale may prompt short‑term price pressure but likely has limited long‑term impact.
Market read
Insider sell of $3.4M could modestly affect KNSA's share price.
What to watch
The 10b5‑1 plan pre‑arranged the sale, reducing negative signaling.
Background
Form 4 filings disclose insider transactions; a senior officer's sale is publicly reported.
Ticker impact
Chief Accounting Officer sold 36,260 shares for $3.4M via a 10b5‑1 plan, reducing his stake to 12,697 shares.
likely short‑term pressure as the market prices in the insider sell.
A $3.4M sale by a senior officer is material for a mid‑cap biotech and often triggers sell‑side sentiment.
Market effects
May raise concerns for the biotech sector about insider confidence.
Limited to U.S. investors tracking KNSA.
Minimal; no broader market effect.
Counterpoint
The sale could be a routine liquidity event unrelated to company fundamentals.
Key entities
- personMegna Michael R
Chief Accounting Officer of Kiniksa Pharmaceuticals International
